(
A) Spir-2-GTBM (purple), represented in sticks, bound to MyoVa-GTD (orange). Shown in orange sticks and labeled are the side chains of the MyoVa-GTD residues whose solvent accessible area is reduced upon complex formation. Hydrogen bonds are represented as dashed lines. (
B) MyoVa-GTD undergoes minor conformational change upon Spir-2-GTBM binding. MyoVa bound to Spir-2-GTBM is shown in orange while apo-MyoVa (PDB ID 4LX1) is white. Upon Spir-2 binding MyoVa, H3 is shifted along the helix axis by 0.9Å and the side chains of Y1596, F1591, K1539, R1528 change slightly their orientations to accommodate the partner. (
C) The MyoVb structure is compatible with Spir-GTBM binding. The Spir-2-GTBM binding site is almost identical in MyoVa-GTD (orange) and MyoVb-GTD (PDB ID 4J5M) (white) (
Nascimento et al., 2013). Residue labeling corresponds to the MyoVb sequence. Residues that are not identical in the MyoVb and MyoVa sequences are labeled in red. (
D) MyoVc binds Spir-GTBM. The Spir-2-GTBM binding site is similar in MyoVa-GTD (orange) and MyoVc-GTD (PDB ID 4L8T) (white) (
Nascimento et al., 2013). Residue labeling corresponds to the MyoVc sequence, the labels for identical residues are in black and for homologous residues in red. (
E) Fluorescin-Spir-2-GTBM peptide (human, amino acids 401–427) binding to MyoVc-GTD measured by microscale thermophoresis. N = 3 experimental repeats.